WE Initate Science & Technology Value,
Always for Caring

WESTVAC

Extensively explore and innovate to prevent and fight human disease

International Leading Vaccine and Immunotherapy Platform

WE
CARE

Creation  Acceleration  Responsibility  Excellence

Media

2022-01-10

Experts From Program for Appropriate Technology in Health (PATH) Visited WestVac Biopharma to Guide Related Work
January 6th to 8th, 2022, Yuan Yuan, head of commerce and business development, GAO Guang, senior technical officer, and DONG Haiyan, senior project officer of Shanghai Representative Office, PATH, visited WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma"), carried out a three-day investigation and training work, and the WestVac Biopharma team accompanied the investigation and held discussion exchange.
Read More
2022-01-06

Progress of WestVac Biopharma's COVID-19 Vaccine Has Attracted International Attention and Reported by Many Overseas Authoritative Media
Recently, the progress of the second generation COVID-19 vaccine of WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma") has attracted international media attention, and has been reported by The Associated Press, Asahi Shinbun, Fox News, Agencia EFE and other overseas authoritative media, causing widespread concern in the global society. In just a few days, more than 600 reports were published.
Read More
2021-12-31

To Boost the High-quality Development of Chengdu, WestVac Biopharma Accelerates the Pace of Scientific＆Technological Innovation
In recent years, Chengdu has focused on the construction of the biopharmaceutical track, accelerated and drove the landing and development of a number of high level projects, and promoted the listing of numerous biopharmaceutical companies on the capital market, which has achieved excellent performance and significant development, and boosted high-quality development of Chengdu by allowing more financial resources to be channeled into the real economy.
Read More

About Us

WestVac Biopharma Co., Ltd. (hereinafter referred to as "WestVac BioPharma"), founded by the research team headed by Professor WEI Yuquan, academician of Chinese Academy of Sciences and Director of the State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, is dedicated to the research, development and commercialization of vaccines and immunotherapies.

With the full support of governments at all levels, Sichuan University and West China Medical Center, WestVac BioPharma has been engaging in the industry chain for COVID-19 vaccine research and development from the onset of the pandemic. Affiliated to Sichuan University, West China Medical Center is the largest national medical center in western China. Its State Key Laboratory of Biotherapy is the only laboratory of its kind with the mandate of "Treating Critical Human Disease with Biotechnology". With the support from West China Medical Center and the State Key Laboratory of Biotherapy, WestVac Biopharma has established an accomplished R&D team of over 150 experts with multi-disciplinary background, including 13 Chang Jiang Scholars/Young Chang Jiang Scholars and 18 winners of the National Science Fund for Distinguished Young Scholars.

Driven by the "capital + innovation" model, role of market and strength in R&D mutually reinforce, thus accelerate the translation of vaccine development into market value. With the strong support of Chengdu Tianfu International Bio-town and continuous investment from influential shareholders such as Sichuan Development, Shanghai Pharma, CICC Capital, China Taiping, Haier Biomedical, WestVac Biological is now valued at more than US$1 billion and listed as a unicorn company in 2021.

In June 2021, the recombinant COVID-19 vaccine (Sf9 cell) developed by WestVac Biopharma completed the Phase I/II clinical trial with satisfactory immunogenicity indicated. At present, Phase III clinical trials are ongoing in Mexico, the Philippines, Indonesia, and Kenya. In August 2021, WestVac BioPharma and Nagasaki University jointly carried out the early phase clinical trial of the recombinant COVID-19 vaccine, which is the first clinical trial of a Chinese vaccine in Japan.

The Chengdu manufacturing base, located in Tianfu International Bio-town, has an annual capacity of 100 million doses of vaccine. A larger facility is under construction in Guangzhou with an expected annual capacity of 500 million doses.

WestVac Biopharma is committed to innovation for a world free of human disease!

Read More

Product R＆D

On July 29, 2020, WestVac Biopharma R&D team published the first COVID-19 vaccine research paper in the journal Nature. They used an innovative recombinant protein technology route for R&D. It's China's first recombinant subunit COVID-19 vaccines expressed in insect cells. The S-RBD gene of the COVID-19 is introduced into insect cells through baculovirus vectors, and the cells are used as a "factory" to produce high-quality recombinant proteins which are then refined and purified. This innovative technology can easily be put into use for rapid and large-scale production of vaccines.

In August 2020, clinical trial was officially approved for the Recombinant Protein COVID-19 Vaccine (Sf9 Cell) . Phase I/II clinical trials have been completed in June 2021, showing good immunogenicity. The Phase III clinical trials have been successfully carried out in Indonesia, the Philippines, Mexico, Kenya, etc. In August 2021, WestVac Biopharma and Nagasaki University in Japan jointly carried out an early clinical trial of the recombinant protein COVID-19 vaccine. This is the first Chinese COVID-19 vaccine clinically tested in Japan, attracting attention from media like China's CCTV, Japan's NHK and others, with enthusiastic responses from all walks of life. In addition, WestVac Biopharma is also accelerating the development of the second-generation COVID-19 vaccine for new variants, racing against time!

In response to emerging mutations, Westvac is accelerating the R&D of a new generation of COVID-19 vaccines and small molecule oral drug targeting the Delta and Omicron strains. On the strength of the mature insect cell expression platform, a new generation of COVID-19 vaccine containing protein subunit antigen that can self-assemble into a stable trimer has been designed based on precise structure. The process study and large-scale preparation of vaccine antigen stock have been completed, and the production process is stable. Besides, oil-in-water emulsion adjuvant (MF59-like adjuvant) is used for the new generation of COVID-19 vaccine, which can stimulate great body immune response, has no potential systemic toxicity, and shows better safety.

In addition to the above-mentioned COVID-19 vaccine, WestVac Biopharma will also endeavor itself to help build a global immune barrier by developing and producing more innovative vaccines from its five major technology platforms in the future, which include insect cell expression system, mRNA vaccine platform, tumor vaccine platform, novel adjuvant platform and novel immunotherapy platform.

Read More

Commercialization

WestVac Biopharma Co., Ltd., with a registered capital of 1.242 billion yuan, is a national high-tech enterprise that focuses on vaccine research, development, manufacturing and commercialization. Located in Chengdu Tianfu International Bio-town, the company is dedicated to developing and manufacturing innovative vaccines and immunotherapy products relying on five major technology platforms, including insect cell expression platform, mRNA vaccine platform, tumor vaccine platform, novel adjuvant platform and novel immunotherapy platform.

WestVac Biopharma has built up facilities for commercial production of vaccines in Chengdu compliant with GMP standards featuring optimal layout, scientific and safe production process and the equipment is basically made in China. WestVac has obtained the drug production license issued by the Sichuan Medical Products Administration. The company has an accomplished team with expertise in vaccine and biopharmaceutical product covering manufacturing, quality, operation and management. Solid production system and quality management system have been established to ensure large-scale production of vaccines.

Read More